ISRCTN68772788已完成未知
Randomised, double-blind trial to compare the treatment effects of Ginkgo biloba extract EGb 761® and pentoxifylline in patients with sub-chronic and chronic tinnitus focussing on psychosocial problems
Dr. Willmar Schwabe GmbH & Co. KG (Germany)0 个研究点目标入组 200 人开始时间: 2012年7月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Outpatients aged = 40 with unilateral or bilateral, sub-chronic or chronic tinnitus (duration > 3 months)
- •2. Tinnitus is the main complaint, other cochlear or vestibular symptoms may be present but less annoying
- •3. Tinnitus is maskable with noise masking
- •4. Annoyance rated at least 3 on the 11-Point Box Scale of tinnitus annoyance at screening and baseline
- •5. Abridged Tinnitus Questionnaire (Mini-TQ) total score rated = 5 at baseline
- •6. Written informed consent to participate in the clinical trial, to randomized treatment and to data recording in accordance with applicable laws
排除标准
- •1. Participation in another experimental drug trial at the same time or within the past 4 weeks before enrolment
- •2. Currently taking any treatments for tinnitus
- •3. Acute or chronic otitis media or vestibular neuritis
- •4. Drug-induced tinnitus
- •5. Significant cardiac or circulatory disorder
- •5.1. Severe (Canadian Cardiovascular Society stage IV) or unstable angina pectoris
- •5.2. Decompensated congestive heart failure (NYHA stage IV)
- •5.3. Significant coronary sclerosis or history of myocardial infarction diastolic blood pressure above 115 mmHg
- •5.4. Hypotension with systolic blood pressure below 110 mmHg and/or diastolic blood pressure below 70 mmHg
- •5.5. Clinically significant cardiac arrhythmias (Lown classes IVb and V, bifascicular bundle branch block)
- •6. Any acute or recent event of bleeding or history of bleeding (in particular intracerebral or retinal bleeding or bleeding from any organ), haemorrhagic diathesis, intake of anticoagulants
- •7. Any surgery within the last 3 months before the start of randomised treatment
- •8. Severe renal or hepatic dysfunction (serum creatinine or serum ASAT, ALAT or gamma-GT above three times the upper limit of the reference range)
- •9. Insulin-dependent or drug-dependent diabetes mellitus
- •10. Systemic lupus erythemathosus (SLE)
- •11. Intake of drugs not permitted during participation in the study, in particular anticoagulants, antidiabetic drugs, insulin, theophylline, cimetidine, psychoactive drugs, other perfusion-enhancing drugs, cognition enhancing drugs or anti-cholinergic drugs
- •12. Active malignant disease (exception: prostate cancer which does not require other than hormone treatment within the next 6 months)
- •13. Known hypersensitivity to Ginkgo biloba extract, pentoxifylline or other methylxanthine substances, or to excipients contained in the tablets
- •14. Active peptic ulcer disease or any gastrointestinal disease with potential impairment of the absorption of orally applied drugs (e.g., Billroth I/II, Crohn's disease, ulcerative colitis, any kind of enterectomy)
- •15. Female patients of childbearing potential without safe contraception (hormonal contraception, oral or transdermal, is considered sufficiently safe; childbearing potential can be denied in case of postmenopausal state for at least 2 years, hysterectomy, bilateral tubal ligation or bilateral oophorectomy)
研究者
相似试验
进行中（未招募）
不适用
Clinical study to investigate the treatment effects of a Ginkgo biloba extract in comparison to the standard medication Pentoxifylline in patients with chronic or subchronic tinnitus (ear noises)EUCTR2011-004697-28-CZDr. W. Schwabe GmbH & Co. KG
进行中（未招募）
1 期
Randomized, double-blind trial comparing the effects of a 3-month clopidogrel regimen, combined with ASA during the first month, versus ASA alone for the acute treatment of patients with TIA or minor stroke - CASTIAEUCTR2005-005763-28-SKSanofi-Aventis Groupe2,400
进行中（未招募）
不适用
Randomized, double-blind trial comparing the effects of a 3-month clopidogrel regimen, combined with ASA during the first month, versus ASA alone for the acute treatment of patients with TIA or minor stroke - CASTIAthe acute treatment of patients with TIA or minor strokeMedDRA version: 8.1Level: HLTClassification code 10008192EUCTR2005-005763-28-PTSanofi-Aventis Groupe2,400
进行中（未招募）
不适用
Randomized, double-blind trial comparing the effects of a 3-month clopidogrel regimen, combined with ASA during the first month, versus ASA alone for the acute treatment of patients with TIA or minor stroke - CASTIAEUCTR2005-005763-28-HUSanofi-Aventis Groupe2,400
进行中（未招募）
1 期
Randomized, double-blind trial comparing the effects of a 3-month clopidogrel regimen, combined with ASA during the first month, versus ASA alone for the acute treatment of patients with TIA or minor stroke - CASTIAthe acute treatment of patients with TIA or minor strokeMedDRA version: 8.1Level: HLTClassification code 10008192EUCTR2005-005763-28-GBSanofi-Aventis Groupe2,400